Omnicell, Inc. announced solid financial results for the fourth quarter of 2025, with total revenues reaching $314 million, a 2% increase from the prior year's fourth quarter. The company reported a GAAP net loss of $2 million, or $0.05 per diluted share, for the quarter, compared to a GAAP net income of $16 million in Q4 2024. Non-GAAP net income for the quarter was $18 million, or $0.40 per diluted share. The company also highlighted the launch of its next-generation dispensing system, Titan XT, aimed at enhancing medication management.

Omnicell delivered robust financial performance in Q3 2025, with total revenues reaching $311 million, a 10% increase year-over-year. The company's GAAP net income was $5 million, and non-GAAP net income was $24 million. Non-GAAP EBITDA also saw an increase to $41 million. The strong results were primarily driven by connected devices and technical services.

Omnicell delivered a strong second quarter in 2025, with total revenues reaching $291 million, a 5% increase year-over-year. The company exceeded its guidance for revenues, non-GAAP EBITDA, and non-GAAP EPS, driven by robust demand for connected devices, technical services, SaaS, Expert Services, and consumables. GAAP net income was $6 million, and non-GAAP net income was $21 million. The company also raised its full-year 2025 guidance for total revenues, non-GAAP EBITDA, and non-GAAP EPS.

Omnicell reported strong financial results for the first quarter of 2025, with total revenues of $270 million, up 10% year-over-year, and non-GAAP net income of $12 million, or $0.26 per diluted share. This exceeded the company's guidance ranges for both metrics. The increase in revenue was primarily driven by the XT Amplify program and growth in SaaS and Expert Services.

Omnicell's Q4 2024 financial results showed a strong performance, with a return to year-over-year revenue growth. The company's total revenues for the quarter reached $307 million, an increase of 19% compared to the same period in 2023. GAAP net income was $16 million, or $0.34 per diluted share, while non-GAAP net income was $28 million, or $0.60 per diluted share.

Omnicell announced its Q3 2024 results, with total revenues of $282 million. GAAP net income per diluted share was $0.19, and non-GAAP net income per diluted share was $0.56. The company raised its 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance.

Omnicell announced strong second quarter results, exceeding their previously issued guidance across all key metrics, including revenue, non-GAAP EBITDA and non-GAAP earnings per share. The company reported total revenues of $277 million and GAAP net income per diluted share of $0.08. They are also raising 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance.

Omnicell announced its first quarter 2024 results, exceeding prior guidance across all key metrics including revenue, non-GAAP EBITDA, and non-GAAP earnings per share. Total GAAP revenues were $246 million, a decrease of 15% compared to the first quarter of 2023. The company reported a GAAP net loss of $16 million, or $0.34 per diluted share, and a non-GAAP net income of $1 million, or $0.03 per diluted share.

Omnicell reported Q4 2023 GAAP revenues of $259 million, a 13% decrease from Q4 2022. The GAAP net loss was $14 million, an improvement from the $28 million net loss in the same quarter of the previous year. The company is undertaking a holistic review of its business to optimize investments and improve profitability.

Omnicell reported Q3 2023 revenues of $299 million, a decrease of 14% year-over-year. GAAP net income was $6 million, or $0.12 per diluted share, while non-GAAP net income was $28 million, or $0.62 per diluted share. The company is taking actions to manage costs and align with anticipated top-line performance.

Omnicell's second quarter 2023 results showed a total GAAP revenue of $299 million, a decrease of 10% compared to the second quarter of 2022. The GAAP net income was $3 million, or $0.08 per diluted share, while the non-GAAP net income was $26 million, or $0.57 per diluted share.

Omnicell's first quarter 2023 saw a decrease in GAAP revenues to $291 million, a net loss of $15 million, or $0.33 per diluted share, but non-GAAP net income was $17 million, or $0.39 per diluted share. The company's full year 2023 guidance is unchanged.

Omnicell's Q4 2022 results showed a decrease in both GAAP and non-GAAP revenues compared to Q4 2021, reflecting macroeconomic challenges and customer budget constraints. The company reported a GAAP net loss, contrasting with the previous year's net income, while non-GAAP net income also decreased.

Omnicell's Q3 2022 GAAP revenues reached $348 million, a 17% increase from Q3 2021. GAAP net income was $17 million, or $0.37 per diluted share, compared to $29 million, or $0.61 per diluted share, in Q3 2021. The company experienced headwinds in point of care products due to capital budget freezes and labor challenges, but saw strong demand for Advanced Services and a record number of Central Pharmacy Dispensing Systems installations.

Omnicell reported a solid performance in Q2 2022, with GAAP revenues of $331 million and non-GAAP revenues of $332 million, despite a modest impact from a ransomware incident. The company reaffirmed its full-year 2022 guidance for product bookings, total GAAP and non-GAAP revenues, non-GAAP EPS, and non-GAAP EBITDA.

Omnicell reported a strong start to 2022 with GAAP and non-GAAP revenues of $319 million. The company's GAAP net income per diluted share was $0.17, while non-GAAP net income per diluted share was $0.83. Omnicell also launched IVX Station, an innovative robotic compounding technology.

Omnicell reported a 25% increase in GAAP revenues for Q4 2021, reaching $311.0 million, driven by strong demand for medication management and adherence automation solutions, as well as contributions from the acquisition of RxInnovation Inc., operating as FDS Amplicare. GAAP net income for the quarter was $14.0 million, or $0.28 per diluted share. The company achieved record bookings, revenues, and non-GAAP EBITDA in 2021.

Omnicell announced strong third quarter results, reflecting continued momentum in the commercial business and robust customer adoption of the cloud-based, Advanced Services portfolio. Total GAAP revenues for the third quarter of 2021 were $296.4 million, up 38.7% from the third quarter of 2020. GAAP net income for the third quarter of 2021 was $29.3 million, or $0.61 per diluted share.

Omnicell announced strong financial results for the second quarter of 2021, with record revenues of $273 million and GAAP net income per diluted share of $0.43. The company's performance reflects robust demand for its solutions and services.

Omnicell announced strong first quarter results, achieving record revenue of $252 million, a 10% increase year-over-year. GAAP net income per diluted share was $0.30, and non-GAAP net income per diluted share was $0.83. The company also added new long-term, sole-source partnership agreements with Top 300 U.S. Health Systems.

Omnicell reported a strong fourth quarter and full year 2020, exceeding expectations and achieving record product bookings of over $1 billion. The company is well-positioned for future growth due to the increasing importance of pharmacy automation and the strategic relevance of its solutions.

Omnicell reported solid financial performance in Q3 2020, exceeding the high end of guidance ranges. The company saw increased new customer wins and bookings, particularly with the top 300 U.S. health systems.

Omnicell reported a decrease in GAAP revenues to $199.6 million, a net loss of $4.3 million, or $0.10 per diluted share, for the second quarter of 2020. The company is navigating challenges related to the COVID-19 pandemic but sees positive indicators for future growth.

Omnicell reported GAAP revenues of $229.7 million, a 13.4% increase from Q1 2019. GAAP net income was $11.3 million, or $0.26 per diluted share, compared to $3.3 million, or $0.08 per diluted share, in the first quarter of 2019. The company withdrew its previously issued full year 2020 financial guidance due to the uncertainty surrounding the COVID-19 pandemic.

Omnicell reported a 17% increase in GAAP revenues for the fourth quarter of 2019, reaching $248.3 million, and a GAAP net income of $22.1 million, or $0.51 per diluted share.